Accuray (ARAY) reported $116.17 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 8.3%. EPS of $0.02 for the same period compares to -$0.10 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $110.95 million, representing a surprise of +4.71%. The company delivered an EPS surprise of +300.00%, with the consensus EPS estimate being -$0.01.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wal ...

Accuray (ARAY) came out with quarterly earnings of $0.02 per share, beating the Zacks Consensus Estimate of a loss of $0.01 per share. This compares to loss of $0.10 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 300%. A quarter ago, it was expected that this radiation oncology company would post a loss of $0.04 per share when it actually produced a loss of $0.04, delivering no surprise.Over the last four quarters, the compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-33301 ACCURAY INCORPORATED Delaware 20-8370041 (State or other jurisdiction of incorporation or organization) (IRS Employer Identificat ...

MADISON, Wis., Feb. 5, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the second quarter ended December 31, 2024.Key Fiscal Q2 Highlights: Strong second quarter and first half results; raising fiscal year 2025 guidance Total net revenue was $116.2 million, an increase of 8 percent year-over-year Net income was $2.5 million compared to a net loss of $9.6 million in the prior year period Adjusted EBITDA was $9.6 million compared to $2.0 million in the prior year ...

"Our strong Q2 performance reflects outstanding execution of our strategies of advancing radiotherapy care, expanding patient access and improving margin performance of the business. We continue to see growing demand for our solutions from our increased commercial presence particularly in fast-growing emerging markets evidenced by the strong momentum in Tomo C System deliveries this quarter, as well as breakthrough wins of our new Helix system, following CE mark in the first fiscal quarter," said Suzanne Wi ...

Company Milestone - Accuray Incorporated announced the completion of treatment for 100 patients using the Tomo® C Radiation Treatment Delivery System at Shandong Cancer Hospital and Institute, marking a significant milestone for the company in addressing the underserved Chinese radiation therapy market [1] - The Tomo C System, developed through the CNNC-Accuray joint venture, has expanded clinical capabilities and enabled potentially curative treatment for more cancer patients in China [1] Market Opportunity - The number of new cancer cases in China is expected to increase by 47% to 7.1 million in 2045, up from 4.8 million in 2022, highlighting the growing demand for advanced radiotherapy technology [2] - The Tomo C System is designed to meet the needs of the underserved Chinese radiation therapy market, with the potential to significantly increase treatment capacity and improve patient outcomes [1][5] Product Impact - The Tomo C System, based on the helical TomoTherapy® platform, enables the treatment of an average of 95 patient fractions per day, significantly increasing the hospital's capacity to provide innovative and effective cancer care [5] - The system integrates helical imaging, advanced treatment planning, and centralized data management to facilitate fast, ultra-precise treatments, allowing more patients to receive care each day [5] Strategic Collaboration - Shandong Cancer Hospital and Institute, a top cancer care center in China, serves over 400,000 patients annually and collaborates with global leaders such as MD Anderson Cancer Center, reinforcing its commitment to innovation and excellence in cancer treatment [4] - The introduction of the Tomo C System expands Accuray's product portfolio in China and reinforces its commitment to providing advanced tools for precision radiotherapy [4][5] Leadership Perspective - Suzanne Winter, President and CEO of Accuray, emphasized the system's ability to treat a wide range of cancer types and its potential to meaningfully increase treatment capacity, enabling more patients to receive care daily [3] - Prof. Yu, President of Shandong Cancer Hospital, highlighted the transformative impact of the TomoTherapy platform and the Tomo C System's role in advancing precision radiotherapy and supporting the "Healthy China Initiative" [5]

MADISON, Wis., Jan. 22, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) will report financial results for the second quarter of fiscal year 2025, ended December 31, 2024, during a conference call hosted by company management at 1:30 p.m. PT/4:30 p.m. ET on February 5, 2025.The conference call dial-in numbers are (833) 316-0563 (USA) or (412) 317-5747 (international). In addition, a dial-up replay of the conference call will be available approximately one hour after the call's conclusion for one wee ...

MADISON, Wis., Jan. 21, 2025 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that Leonel Peralta is joining the company as Senior Vice President, Chief Operations Officer, effective February 3, 2025. Mr. Peralta will be responsible for leading worldwide manufacturing operations including driving alignment of operations with corporate business goals, maximizing supply chain profitability and efficiency, and ensuring processes support best-in-class customer service. He will report to Accur ...

Momentum investing is essentially the opposite of the tried-and-tested Wall Street adage -- "buy low and sell high." Investors following this investing style typically avoid betting on cheap stocks and waiting long for them to recover. They believe instead that one could make far more money in lesser time by "buying high and selling higher."Everyone likes betting on fast-moving trending stocks, but it isn't easy to determine the right entry point. These stocks often lose momentum when their future growth po ...

Accuray Incorporated (ARAY) recently announced that its Radixact SynC System and CyberKnife S7 System have been approved by the Chinese National Medical Products Administration. These approvals are likely to enable medical care teams to provide patients in China with the most advanced Accuray radiation therapy solutions.The CyberKnife S7 System is the latest generation CyberKnife platform, and the introduction of the Radixact SynC System marks the first approval in the country for the ClearRT kVCT imaging a ...